PDE5 inhibitor use was associated with a 35% decreased risk for CRC in male patients with a history of a benign colorectal neoplasm, and the decrease was associated with increasing cumulative dose of PDE5 inhibitors.
All articles by Andy Kistler, MD, PharmD
Latest News Your top articles for ThursdayFor More Personalized News
Haymarket Medical NetworkTop Picks
Continuing Medical Education (CME/CE) Courses